Evidence map›Paper›PMID 40495950›Full record

ArticleWorld journal of gastroenterology2025

Multi-parameter magnetic resonance imaging of zebularine in liver fibrosis treatment and calcineurin/

Shi-Yi Lyu, Wang Xiao, Yan-Jing Chen, Qiu-Ling Liao, Ye-Yu Cai, Cheng Yu, Jia-Yi Liu, Huan Liu, Min-Ping Zhang, Yu-Lu Ren and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Biliary atresia-related liver fibrosis.Frontiers in cell and developmental biology · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Shi-Yi LyuDepartment of Radiology, Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.
Wang XiaoDepartment of Gastrointestinal Surgery, Yiyang Central Hospital, Yiyang 413099, Hunan Province, China.
Yan-Jing ChenDepartment of Radiology, Peking University Third Hospital, Beijing 100083, China.
Qiu-Ling LiaoDepartment of Radiology, Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.
Ye-Yu CaiDepartment of Radiology, Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.
Cheng YuDepartment of Radiology, Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.
Jia-Yi LiuDepartment of Oncology, Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.
Huan LiuDepartment of Radiology, Second Affiliated Hospital, South China University, Hengyang 421001, Hunan Province, China.
Min-Ping ZhangDepartment of Ultrasound, Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.
Yu-Lu RenDepartment of Radiology, Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.
Qi-Ling YuDepartment of Radiology, Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.
Yi-Ming QiDepartment of Radiology, Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.
En-Hua XiaoDepartment of Radiology, Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.
Yong-Heng LuoDepartment of Radiology, Second Xiangya Hospital of Central South University, Changsha 410011, Hunan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatic stellate cell (HSC) activation is key to liver fibrosis. Targeting DNA methylation shows promise. Zebularine, a methylation inhibitor, may suppress HSC activation

aimTo clarify the anti-fibrosis mechanism and MRI-evaluated efficacy of zebularine.

methods

resultsZebularine upregulated RCAN1.4 protein (

conclusionZebularine may reduce LX-2 activation and extracellular matrix deposition

Indexed as

CalcineurinCytidineLiver CirrhosisLiver Cirrhosis, ExperimentalMagnetic Resonance ImagingNFATC Transcription FactorsAnimalsCalcium-Binding ProteinsCarbon TetrachlorideCell LineDisease Models, AnimalHepatic Stellate CellsHumansIntracellular Signaling Peptides and ProteinsLiverMaleCalcineurinCalcium-Binding ProteinsCarbon TetrachlorideCytidineDSCR1 protein, mouseIntracellular Signaling Peptides and ProteinsMuscle ProteinsNFATC Transcription Factorspyrimidin-2-one beta-ribofuranosideTransforming Growth Factor beta1Calcineurin/NFAT3 pathwayDNA methylationHepatic stellate cellLiver fibrosisRegulator of calcineurin1.4Zebularine

Identifiers

PMID40495950
PMCPMC12146936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.